정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 919 | Enrolling by invitation | PET/CT Imaging in COVID-19 Patients | SARS-CoV-2 Infection | Drug: 18F-αvβ6-BP | Early Phase 1 | University of California, Davis | OTHER | 10 | All | 18 Years | University of California Davis, Sacramento, California, United States |
| 918 | Recruiting | PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants | Healthy Participants | Drug: Dabigatran Drug: PF-07321332/ritonavir + Dabigatran Drug: Ritonavir + Dabigatran |
Phase 1 | Pfizer | INDUSTRY | 24 | All | 18 Years ~ 60 Years | Research Centers of America ( Hollywood ), Hollywood, Florida, United States |
| 917 | Terminated | Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects | Coronavirus Disease 2019 (COVID-19) | Biological: CSL760 | Phase 1 | CSL Behring | INDUSTRY | 12 | All | 18 Years ~ 65 Years | CMAX Clinical Research, Adelaide, Australia |
| 916 | Not yet recruiting | Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment | COVID-19 | Drug: Ascorbic Acid | Phase 2 | Thomas Jefferson University | OTHER | 66 | All | 18 Years | |
| 915 | Recruiting | Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults | Covid19 | Biological: CVXGA1 low dose Biological: CVXGA1 high dose |
Phase 1 | CyanVac LLC | INDUSTRY | 80 | All | 18 Years ~ 75 Years | Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States University of Rochester Medical Center, Rochester, New York, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Research Your Health, Plano, Texas, United States |
| 914 | Recruiting | Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients | Covid19 | Drug: NTR-441 Drug: Placebo |
Phase 1 | Neutrolis | INDUSTRY | 92 | All | 18 Years ~ 99 Years | Medical University of Vienna, Department of Infectiology and Tropical Medicine, Vienna, Austria Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria |
| 913 | Not yet recruiting | Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol | SARS-CoV2 Infection | Biological: Ad5-triCoV/Mac Biological: ChAd-triCoV/Mac |
Phase 1 | McMaster University, Canadian Institutes of Health Research (CIHR) | OTHER | 30 | All | 18 Years ~ 65 Years | McMaster University Medical Centre, Hamilton, Ontario, Canada |